"Viking Therapeutics' Oral Weight-Loss Drug Shows Promise in Phase 1 Study"
Viking Therapeutics' experimental weight-loss tablet, VK2735, showed promising results in a small early-stage trial, with the highest 40-milligram dose leading to a 3.3% weight loss in participants. The company's shares rose 15% following the news. Viking plans to continue testing higher doses and expects to initiate a mid-stage study in obese patients later this year. The drug's oral version could offer a more convenient option for patients, especially those who have achieved significant weight loss with the injectable version.